Vera Therapeutics (NASDAQ:VERA) is one of the 17 biotechnology stocks with more than 50% upside.
On January 27, Anupam Rama of JPMorgan maintained an Overweight rating on Vera Therapeutics (NASDAQ:VERA) with a $96 price target. His estimates imply upside of more than 127%.
Copyright: dolgachov / 123RF Stock Photo
Rama believes the shares offer strong upside potential from the current trading range. He anticipates that as competitors’ clinical data emerges, the stock price of Vera Therapeutics (NASDAQ:VERA) could rise toward a more appropriate risk-adjusted valuation.
Back on January 16, Cantor Fitzgerald also reiterated its Overweight rating on Vera Therapeutics (NASDAQ:VERA). Based on a $100 target price, the stock offers nearly 137% upside at the current level.
The firm highlighted that conditions appear favorable for atacicept’s possible approval to treat IgA-related kidney disorder. It also pointed towards the company’s solid foundation for a successful launch, indicating a strong opportunity for market entry once it has obtained regulatory approvals.
Vera Therapeutics (NASDAQ:VERA) is a late-stage clinical biotechnology company that addresses immunological conditions. The company develops and commercializes transformative treatments for serious diseases, including immunoglobulin A nephropathy. It is currently developing MAU868, which is a monoclonal antibody for BK viremia infections in transplant patients.
While we acknowledge the potential of VERA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 15 Most Promising Mid-Cap Healthcare Stocks Under $50 and 11 Most Promising Small-Cap Industrial Stocks Under $50.
Disclosure: None. This article is originally published at Insider Monkey.
